Isolated Polypeptide Inhibiting Caspase-2 Cleavage in Tauopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily focus on alleviating symptoms and reducing neuropathology without addressing the underlying cause, particularly the form of tau protein (tau*) that initiates memory loss in tauopathy, which is distinct from neurofibrillary tangle formation.
Innovation Solution
Development of an isolated polypeptide comprising a core pentapeptide, potentially with appended amino acids, designed to inhibit caspase-2-dependent tau cleavage, thereby reducing the production of tauopathic markers like TCP35, TCP30, and TCP40, and administering these polypeptides to inhibit caspase-2 activity in subjects with or at risk of tauopathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease focus on alleviating symptoms and reducing neuropathology, then clinical symptoms may be temporarily improved, but the underlying cause (tau* protein and caspase-2-dependent tau cleavage) remains unaddressed
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (caspase-2-dependent tau cleavage) from the complex Alzheimer's disease pathology. By focusing on the isolated enzymatic step rather than the entire disease process, the treatment addresses the root cause while maintaining mechanistic simplicity through targeted inhibition.
Solution Approach 2:
The patent employs preliminary action by preventing the formation of pathogenic tau fragments (TCP35, TCP30, TCP40) through early inhibition of caspase-2. This proactive approach stops the disease progression before significant neuropathology accumulates, rather than attempting to reverse established damage.
2Reliability
If isolated polypeptides are designed to inhibit caspase-2-dependent tau cleavage, then production of tauopathic markers (TCP35, TCP30, TCP40) is reduced, but the complexity of polypeptide design and optimization increases
Solution Approach 1:
The patent segments the tau protein into specific cleavage sites recognized by caspase-2, and designs polypeptides that target these discrete segments. This segmentation allows for precise inhibition of the pathological cleavage event without requiring complex full-length protein interactions, simplifying the inhibitor design while maintaining efficacy.
Solution Approach 2:
The patent optimizes polypeptide parameters such as amino acid sequence, length, and structural conformation to achieve effective caspase-2 inhibition. By systematically varying these parameters, the invention identifies optimal polypeptide configurations that maximize inhibition efficacy while minimizing structural complexity.
3Duration of action of stationary object
If treatments address the underlying cause of tauopathy through caspase-2 inhibition, then long-term disease prevention is improved, but the risk of off-target effects and side effects increases
Solution Approach 1:
The patent applies local quality by designing polypeptides with specific structural features and amino acid sequences that confer high specificity for caspase-2. The polypeptides are engineered to recognize unique characteristics of the caspase-2 active site or substrate binding region, ensuring localized and selective inhibition that spares other caspases and cellular processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively targets the underlying cause of tauopathy by inhibiting caspase-2-dependent tau cleavage, potentially ameliorating clinical symptoms and preventing the development of tauopathic conditions such as Alzheimer's disease by reducing the levels of pathogenic tau fragments.
Implementation Method 1
isolated polypeptide that comprises an amino acid sequence designed to interfere with caspase-2-dependent tau cleavage
Data Source
AI summary
Disclosed herein are isolated polypeptides, antibody preparations, treatment methods, diagnostic methods, and screening methods related to tauopathy. Generally, the isolated polypeptide includes a core pentapeptide, with the proviso that the isolated polypeptide is not a native full-length tau protein. Generally, the antibody preparations include antibody that specifically binds to SEQ ID NO:12. Generally, the treatment methods include administering to a subject a composition that includes the isolated polypeptide. Generally, the diagnostic methods includes contacting a sample from a subject with an antibody preparation that includes antibody that specifically binds to SEQ ID NO:12, and then detecting a ligand in the sample that specifically binds the antibody preparation. Generally, the screening method includes incubating a mixture of caspase-2, a labeled caspase-2 cleavage substrate, and a test compound under conditions effective to permit the caspase-2 to cleave the caspase-2 cleavage substrate, then determining whether the test compound inhibits cleavage of the substrate by caspase-2.